85
BIBLIOGRAFIA
Adjei AA A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 1999; 48: 265-277
Adjei AA, Davis JN, Bruzek LM et al. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001; 7: 1438-1445
Adjei AA, Erlichman C, Sloan AJ et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitarget antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 8: 1748-1757
Ando Y, Saka H, Ando M et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;
60: 6921-6926
Andre T, Boni C, Mounedji-Boudiaf L et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators.Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343- 2351
Arango D, Wilson AJ, Shi Q et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004; 91: 1931-1946
Arnould S, Guichard S, Hennebelle I et al. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line. Biochem Pharmacol 2002; 64: 1215-1226 Arnould S, Hennebelle I, Canal P et al. Cellular determinants of oxaliplatin
sensitivity in colon cancer cell lines. Eur J Cancer 2003; 39 :112-119
Assaraf Y, Goldmann ID. Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 1997; 272: 174-178
Atkins JN, Jacobs SA, Wieand HS et al. Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer 2005; 5: 181-187
Barbour KW, Berger SH, Berger FG. Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol Pharmacol 1990; 37: 515-518
Batty DP, Wood RD. Damage recognition in nucleotide excision repair of DNA.
Gene 2000; 241: 193-204
Boarman DM, Baram J e Allegra CJ. Interaction of polyglutamyl derivatives of methotrexate, 10-deazaaminopterin, and dihydrofolate with dihydrofolate reductase. Cancer Res 1986; 46: 5020-5023
Borenfreund E, Babich H, Martin-Alguacil N. Rapid chemosensitivity assay with human normal and tumor cells in vitro. In Vitro Cell Dev Biol 1990; 26:
1030-1034
Branch P, Masson M, Aquilina G et al. Spontaneuous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000; 19: 3138-3145
Britten CD, Izbicka E, Hilsenbeck S et al. Activity of multitarget antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 1999; 44: 105-110
Bunz F, Hwang PM, Torrace C et al. Disruption of p53 in human cancer cells
86
alters the responses to therapeutic agents. J Clin Invest 1999; 194: 263- 269
Bustin SA, Dorudi S. Molecular assessment of tumour stage and disease recurrence using PCR-based assays. Mol Med Today 1998; 4: 389-396 Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal
cancer. Why we still don't know. JAMA 1988; 259: 3571-3578
Calvert H, Walling JW. Clinical studies whit MTA. B J of Cancer 1998; 78: 35-40 Calvert H, Walling JW. Folate status and the safety profile of antifolates. Semin
Oncol 2002; 29: 3-7
Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995; 64: 721-762
Chang IY, Kim MH, Kim HB et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005; 327: 225-233
Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007; 6: 404-417
Chen J, Suter B. Xpd, a structural bridge and a functional link. Cell Cycle 2003;
2:503-506
Chen R, Rabinovitch PS, Crispin DA et al. The initiation of colon cancer in a chronic inflammatory setting.Carcinogenesis. 2005; 26:1513-9
Chen VJ, Bewley JR, Andis SL et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998; 78: 27-34
Chen VJ, Bowley JR, Andis SL et al. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM CELLS. Semin Oncol 1999; 26: 48-54
Cho KR, Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence.Cancer. 1992; 70:1727-1731
Chong L, Tattersall MHN. 5,10-dideazatetrahydrofolic acid reduces toxicity and deoxyadenosina triphosphate pool expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase. Biochemical Pharmacol 1995; 49: 819-827
Chow M, Rubin H. Selective killing of preneoplastic and neoplastic cells by methotrexate with leucovorin. Proc Natl Acad Sci USA 1998; 95: 4550- 4555.
Chu E, Allegra CJ. The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul 1996; 36: 143-163
Chu E, Drake JC, Koeller DM et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 1991; 39: 136-143
Chu E, Takimoto CH, Voeller D et al. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro.
Biochemestry 1993; 32: 4756-4760
Climie S, Ruiz-Perez L, Gonzalez-Pacanowska et al. Saturation site-directed mutagenesis of thymidylate synthase. J Biol Chem 1990; 265: 18776-18779 Cotran R, Kumar V, Collins T. Robbins Le Basi Patologiche delle Malattie 2000;
VI edizione
Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 317-325 Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of
87
drugs of the future: oxaliplatin. Cell Mol Life Sci 2002; 59:1914-1927
Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 2004; 9: 282-294
Duell EJ, Wiencke JK, Cheng TJ et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000; 21: 965-971
Dybdahl M, Vogel U, Frentz G et al. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma.
Cancer Epidemiol Biomarkers Prev 1999; 8:77-81
Evans WE, Relling MV. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 1999; 289: 487-491.
Faivre S, Chan D, Salinas R et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 2003; 66: 225-237
Felix CA, Walker AH, Lange BJ et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natrl Acad Sci USA 1998; 95: 13176- 13181
Fresno Vara JA, Casado E et al. PI3K/Akt signalling pathway and cancer.
Cancer Treat Rev 2004; 30: 193-204
Fujishima H, Nakano S, Masumoto N et al. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Oncol Res 1997; 9: 167-172
Fukuoka K, Adachi J, Nishio K et al. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn J Cancer Res 1997; 88:1009-1016
Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first- line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136- 147
Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004 15; 22: 1797-1806
Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-118 Giovannucci E, Willett WC. Dietary factors and risk of colon cancer. Ann Med
1994; 26: 443-52
Goan YG, Zhou B, Hu E et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycitidine in the human KB cancer cell line. Cancer Res 1999; 59: 4204-4207
Goldberg RM. Advances in the treatment of metastatic colorectal cancer.
Oncologist 2005; 10: 40-48
Gorlick R, Goker E, Trippett T et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335: 1041-1048.
Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 2007; 33:
565-577
Greene PJ, Maley F, Pedersen-Lane J, Santi DV. Catalytically active cross- species heterodimers of thymidylate synthase. Biochemistry 1993; 32:
10283-10288
Guichard S, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5- fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998; 55: 667-
88 676
Habeck LL, Leitner TA, Shackelford KA et al. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors.
Cancer Res 1994; 54: 1021-1026
Habeck LL, Mendelsohn LG, Shih C et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
Mol Pharmacol 1995; 48: 326-333
Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity.
Cancer Res 1997; 57: 229-233
Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta 2004; 1697:
3-16
Hanauske AR, Chen V, Paoletti P, Cletniyikiza T. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist 2001; 6: 363-373
Hao CY, Ji JF. Surgical treatment of liver metastases of colorectal cancer:
Strategies and controversies in 2006.Eur J Surg Oncol 2006; 32: 473-483 Holden JA. Human deoxyribonucleic acid topoisomerases: molecular targets of
anticancer drugs. Ann Clin Lab Sci 1997; 27:402-412
Huang Y, Ray S, Reed JC et al. Estrogen increases intracellular Bcl-2 to Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997; 42:73-81
Iwasaki H, Huang P, Keating MJ et al. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90: 270-278
Iyer L, Ratain MJ. Clinical Oncology Update Pharmacogenetics and Cancer Chemotherapy. Eur J Cancer 1998; 34:1493-1499
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics CA Cancer J Clin 56: 106-130
Johnston PG, Mick R, Recant W, et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997; 89: 308-213.
Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact.
Br J of Cancer 1998; 78: 1-7
Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer.
Cancer 2002; 95: 928-932
Kitchens ME, Forsthoefel AM, Barbour Kw et al. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Mol Pharmacol 1999; 56: 1063-1070
Kumar P, Kisliuk RL, Gaumont Y et al. Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells. Biochem Pharmacol 1990; 40: 2651-2660
Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;
31: 90-105
Li WW, Lin JT, Schweitzer BI et al. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res 1992; 52: 3908-3913 Lin X, Howell SB. DNA mismatch repair and p53 function are major
determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 2006; 5: 1239-1247
Longley DB, Bover J, Allen WL et al. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil
89
and antifolates. Cancer Res 2002; 62: 2644-2649
Lu X, Errington J, Chen VJ et al. Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 2000; 6: 271-277
Lunn RM, Helzlsouer KJ, Parshad R et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000; 21: 551-555
Maindrault-Goebel F, Louvet C, André T et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999; 35: 1338-1342
Martinez SR, Bilchik AJ. Quality control issues in the management of colon cancer patients.Eur J Surg Oncol. 2005; 31:616-629
Matsumoto S, Igishi T, Hashimoto K et al. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer. Int J Oncol 2004; 25: 1311-1318
Mauritz R, Peters GJ, Priest DG et al. Multiple mechanisms of resistance to methotrexate and novel antifolate in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002;
63: 105-115
McLeod HL, Cassidy J, Powrie RH et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res 2000; 6: 2677-2684 Mendelsohn LG, Shih C, Schultz RM et al. Biochemistry and pharmacology of
glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest New Drugs 1996; 14: 287-294
Mey V, Giovannetti E, De Braud F et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006; 95: 289-297 Meyer UA. Genotype or phenotype: the definition of a pharmacogenetic
polymorphism. Pharmacogenetics 1991; 1: 66-7
Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13 : 2936-2943
Motulsky AG. Drug reactions, enzymes, and biochemical genetics. JAMA 1957;
165: 835-836
Novakovic P, Stempak JM, Sohn KJ, Kim YI. Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells.
Carcinogenesis 2006; 27: 916-924
Ojima E, Inoue Y, Watanabe H et al. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Oncol Rep 2006;16: 1085-1091 Orlando C, Pizzani P, Pazzagli M. Developments in quantitative PCR. Clin
Chem Lab Med 1998; 36: 255-269
Park DJ, Stoehlmac J, Zh herang W et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8658
Park DJ, Zhang W, Stoehlmacher J et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;
1: 162-166
Pauletti G, Lai E, Attardi G. Early appearance and long-term persistence of the submicroscopic extrachromosomal elements (amplisomes) containing the amplified DHFR genes in human cell lines. Proc Natl Acad Sci USA 1990;
90 87: 2955-2959
Peters GJ, Backus HH, Freemantle S et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:
194-205
Peters GJ, van der Wilt CL, van Moorsel CJ et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87: 227-253
Postmus PE, Bunn PA. Pemetrexed as a single agent in the terapy of avanced lung cancer. Semin Oncol 2002; 29: 17-22
Ramachandran C, Melnick SJ. Multidrug resistence in human tumors-molecular diagnosis and clinical significance. Molecular Diagnosis 1999; 4: 35-53 Raymond E, Faivre S, Chaney S et al. Cellular and molecular pharmacology of
oxaliplatin. Mol Cancer Ther 2002a; 1: 227-235
Raymond E, Louvet C, Tournigand et al. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Int J Oncol 2002b; 21: 361- 367
Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999; 59: 3968-3971
Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13: 2842-2850 Rosell R, Crinò L. Pemetrexed combination therapy in the treatment of non-
small cell lung cancer. Semin Oncology 2002; 29: 23-29.
Rots MG, Willey JC, Jansen G et al. mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia 2000;14: 2166-2175
Ruo L, Guillem JG. Surgical management of primary colorectal cancer. Surg Oncol 1998; 7:153-163
Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil leucovorin (FL) in stage III colorectal cancer. J Clin Oncol 2004; 22: 3500-3508
Schultz RM, Patel VF, Worzalla JF et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19: 437-443
Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92: 595- 600
Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-1123
Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;
19: 4298-4304
Sigmond J, Backus HH, Wouters D et al. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
91
Biochem Pharmacol 2003; 66: 431-438
Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: modulating effect of types and amount of dietary fat on ras-p21 function during promotion and progression stages of colon cancer. Cancer Res 1997; 57: 253-258.
Smith GK, Duch DS, Dev IK et al. Metabolic effects and kill of human T-cell leukemia by 5-deazaacyclotetrahydrofolate, a specific inhibitor of glycineamide ribonucleotide transformylase. Cancer Res 1992; 52: 4895- 4903
Smith PG, Marshman E, Calvert AH et al. Prevention of thymidine and hypoxantine rescue from MTA (LY231514) growth inhibition by dypiridamole in human lung cancer cell lines. Semin Oncol 1999; 26: 63-67 Spitz MR, Wu X, Wang Y et al. Modulation of nucleotide excision repair capacity
by XPD polymorphisms in lung cancer patients. Cancer Res 2001 15; 61:
1354-1357
Srimatkandada S, Schweitzer BI, Moroson BA et al. Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J Biol Chem 1989; 264: 3524-3528
Stone SR, Montgomery JA, Morrison JF. Inhibition of dihydrofolate reductase from bacterial and vertebrate sources by folate, aminopterin, methotrexate and their 5-deaza analogues. Biochem Pharmacol 1984; 33: 175-179
Strobel T, Kraeft SK, Chen LB et al. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemiotherapy-induced cell death. Cancer Res 1998; 58: 4776-4781 Taylor EC, Kuhnt D, Shih C et al. A dideazatetrahydrofolate analogue lacking a
chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992; 35: 4450-4454
Tesei A, Ricotti L, De Paola F et al. In vitro schedule-dependent interactions between the multitarget antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 2002; 8: 233-239
Tirode F, Busso D, Coin F, Egly JM. Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7. Mol Cell 1999; 3: 87-95
Toffoli G, Veronesi A, Boiocchi M et al. MTHFR gene polymorphism and severe toxicity during adjuvant trarment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000;
11: 373-374
Tonkinson JL, Marder P, Andis SL et al. Cell cycle effects of antifolate antimetabolites implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521-531 Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521- 531
Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59: 3671-3676
Twelves C, Wong A, Nowacki M et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
van der Kolk DM, de Vries EG, van Putten WJ et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000; 6: 3205-3214
92
van der Wilt CL, van Laar JA, Gyergyay F et al. Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice. Eur J Cancer 1992; 28A: 2017-2024
van Kuilemburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluoruracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712
van Triest B, Pinedo HM, van Hensberger Y et al. Thymidylatesynthase level as the main predictive parameter for sensitivity to 5-fluoruracil, but not for folate based thymidylate synthase inhibitors, in 13 non selectted colon cancer cell lines. Clin Cancer Res 1999; 5: 643-654
Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501-1518 Venter JC. The sequence of the human genome. Nature 2001; 291: 1304.
Viguier J, Boige V, Miquel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
Clin Cancer Res 2005; 11: 6212-6217
Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 2000; 461: 197-210
Wang Y, Zhaor R, Goldmann ID et al. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 2003; 65: 1163-1170
Webley SD, Welsh SJ, Jackman A et al. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J of Cancer 2001; 85: 446-452
Welsh SJ, Titley J, Brunton L et al. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res 2000; 6: 2538-2544
Wilson MD, Ruttan CC, Koop BF, Glickman BW. ERCC1: a comparative genomic perspective. Environ Mol Mutagen 2001; 38: 209-215
Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553-3559
Xu Z, Chen ZP, Malapetsa A et al. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 2002; 13: 511-519 Yeh KH, Cheng AL, Wan JP et al. Down-regulation of thymidylate synthase
expression and its steady-state mRNA by oxaliplatin in colon cancer cells.
Anticancer Drugs 2004; 15: 371-376
Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16: 555-560
Zamorano PL, Mahesh VB, Brann DW. Quantitative RT-PCR for neuroendocrine studies. A minireview. Neuroendocrinology 1996; 63: 397- 407
Zhao R, Gao F, Wang Y et al. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 2001; 276: 1114-1118
